Leukemia, AML, American Society Of Hematology discussed on Novel Targets

Novel Targets


This episode comes from the two thousand and sixteen annual meeting the American society of hematology, commonly known as ash we've called it controversies in hematology because each of the expert show here officer, very personal view. The not everyone is going to agree with leading them fomer specialist tells us what he really thinks about Carty. So I I'm not ready to go to my desert island with only a cartesian L agent to treat whatever patient, I might encounter and have the right targets being chosen for pioneering trial in acute myeloid leukemia. AM, oh, you're over sixty the survival rates. No more than about two percent at ten years. We have to do something better in ceelo, chronic lymphocytic. Leukemia will hear what it liberal expert for it was exciting at the me too. So it's sort of tastes great less filling version of brew. Linden. Now is it really better in his own little trial. It seems to be better. Finally, one of the prominent topics at fishes ash meeting was sickle cell disease, while we're excited about novel therapies, a lot of ad is actually controlling the disease, but what about cure? We'll hear more about the potential for gene editing and gene therapy later immature. This so despondent punch and Intech over the past two years. They sponsored fifteen episodes would grateful for their support and just to be clear if we do mention any products we made an independent Detroit decision to do. So our sponsors have no control of the topics. We cover who we interview of questions we asked. So let's start with a mentioned for the leukemia and lymphoma society at Ashby out to major new initiative called beat AML, this postering and adaptive clinical trial that will investigate multiple targets with multiple drugs from different companies. This approach has never been done before AML. Will it be a game changer? I spoke to one of lead investigators. I'm Brian Drucker director of the Oregon Health and science university night, Ken through toot in Portland, Oregon beat AML really is groundbreaking. We're going to be able to assign patients over sixty two treatment based on their genetic makeup of leukemia within seven days of diagnosis and our goals to try to have a treatment for every single patient who enrolls, and that's truly remarkable.

Coming up next